coagulopathy secondary to traumatic hemorrhagic shock
Conditions
Interventions
Trade Name: KANOKAD 25 UI/ml de facteur IX, poudre et solvant pour solution injectable
Product Name: kanokad
Pharmaceutical Form: Powder and solution for solution for injection
Pharmaceutical form of
Sponsors
University Hospital Grenoble
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: NA Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 350 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: NA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: NA;Secondary Objective: NA;Primary end point(s): NA;Timepoint(s) of evaluation of this end point: NA | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA | — |
Countries
France
Contacts
Public Contactprincipal investigator
University Hospital Grenoble
Outcome results
None listed